PMID- 21121872
OWN - NLM
STAT- MEDLINE
DCOM- 20110331
LR  - 20161125
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 10
IP  - 1
DP  - 2011 Jan
TI  - Clinical safety of tocilizumab in rheumatoid arthritis.
PG  - 123-31
LID - 10.1517/14740338.2011.537256 [doi]
AB  - IMPORTANCE OF THE FIELD: Tocilizumab is a new biologic disease-modifying 
      antirheumatic drug directed against the activity of IL-6, a key pro-inflammatory 
      cytokine in the pathogenesis of rheumatoid arthritis (RA). This drug has proved 
      highly effective in RA patients, including those who had previously not responded 
      to anti-TNFs. As side effects are a major cause for discontinuing biologic 
      therapy, the present article focuses on the tolerability profile of tocilizumab. 
      AREAS COVERED IN THIS REVIEW: This review describes the adverse events (AEs) 
      reported in RA patients treated with tocilizumab. Most data are derived from 
      controlled clinical trials and their open-label extensions. WHAT THE READER WILL 
      GAIN: The reader will gain a comprehensive review of treatment-emergent AEs 
      associated with tocilizumab therapy. These AEs include infections, including 
      opportunistic infections, infusion and hyper-sensitivity reactions, 
      gastrointestinal perforation, and laboratory test abnormalities, especially 
      hepatic transaminase elevations, altered lipid profile and neutropenia. TAKE HOME 
      MESSAGE: Based on current data, tocilizumab appears to have an acceptable safety 
      profile inasmuch as most AEs were manageable or controllable. However, results 
      from large scale pharmacoepidemiological investigations and appropriate 
      post-marketing surveillance are awaited to identify the full spectrum of AEs and 
      define the true benefit:risk ratio of tocilizumab.
FAU - Bannwarth, Bernard
AU  - Bannwarth B
AD  - University Hospital Pellegrin & Division of Therapeutics, Department of 
      Rheumatology, University Victor Segalen, Bordeaux, France. 
      bernard.bannwarth@u-bordeaux2.fr
FAU - Richez, Christophe
AU  - Richez C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101202
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Antibodies, Monoclonal/*adverse effects/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/*adverse effects/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Interleukin-6/antagonists & inhibitors
MH  - Randomized Controlled Trials as Topic
EDAT- 2010/12/03 06:00
MHDA- 2011/04/01 06:00
CRDT- 2010/12/03 06:00
PHST- 2010/12/03 06:00 [entrez]
PHST- 2010/12/03 06:00 [pubmed]
PHST- 2011/04/01 06:00 [medline]
AID - 10.1517/14740338.2011.537256 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2011 Jan;10(1):123-31. doi: 10.1517/14740338.2011.537256. 
      Epub 2010 Dec 2.